The idea that bone marrow-derived macrophages can help fight Alzheimer’s pathology is not new. Previous work from the same group and others showed that these cells, when they do manage to enter the brain, act as reinforcements for microglia, the brain’s resident immune cells. Microglia in the Alzheimer’s brain gradually become exhausted and dysfunctional, losing their ability to engulf amyloid plaques efficiently. Monocyte-derived macrophages arriving from the circulation can compensate, reducing inflammation and slowing cognitive decline in mouse models of amyloidosis. Boosting their spontaneous recruitment has been shown to ameliorate disease in several experimental settings. The puzzling question was why, if these cells are beneficial, the body does not send more of them to the battlefield. The new study provides a striking answer: the supply line itself is broken.

Using the 5xFAD mouse model of familial Alzheimer’s disease, the researchers traced the problem back to hematopoietic stem cells, the master progenitors residing in the bone marrow that give rise to all blood cell types. In healthy animals, a large fraction of these stem cells remain in a state of quiescence, a dormant mode that preserves their long-term capacity to replenish the immune system. In the Alzheimer’s mice, this quiescence was lost. The stem cells were being pushed out of dormancy prematurely, and the downstream assembly line, a process called myelopoiesis that generates monocytes and other myeloid cells, was visibly impaired. Single-cell RNA sequencing of the femur and skull bone marrow revealed that multipotent progenitors in the diseased animals carried a strong transcriptional signature of type I interferon activation, along with defects in their commitment to the monocyte lineage.

Type I interferons are best known as antiviral cytokines, the body’s first response to infection. But when their signaling persists without resolution, they can be deeply harmful to stem cells. Prior studies have shown that chronic interferon exposure drives hematopoietic stem cells out of quiescence, exhausts their self-renewal capacity, and accelerates aging of the blood system. The new work extends this concept to neurodegeneration. The researchers detected elevated levels of interferon-beta in the bone marrow of the Alzheimer’s model mice, and when they cultured stem cells in a dish with interferon-beta, monocyte differentiation was suppressed in a dose-dependent manner. The lymphocyte compartment, by contrast, remained largely unaffected, indicating a selective attack on the myeloid branch of the immune system.

Crucially, the damage was not confined to mice. By reanalyzing single-cell transcriptomic datasets from human patients, the team found that circulating classical monocytes in the blood of Alzheimer’s patients, and monocyte populations in their cerebrospinal fluid, displayed phenotypic abnormalities that closely mirrored those seen in the mouse bone marrow. A shared set of disease-relevant functions was dysregulated across species, and the patients’ monocytes carried a molecular score that distinguished them not only from healthy controls but also, progressively, from people with mild cognitive impairment. This suggests that the bone marrow dysfunction is not a rodent artifact but a feature of the human disease, potentially tracking its progression.

The mechanistic link to failed brain homing came down to a single receptor. The researchers found that classical monocytes in the Alzheimer’s mice expressed abnormally high levels of CXCR4, a receptor that keeps cells anchored in the bone marrow by responding to its ligand CXCL12. Monocytes from the diseased marrow migrated poorly toward CXCL12 gradients in Transwell assays, and their ability to leave the marrow and reach the brain was compromised. When the team treated mice with AMD3100, a drug that blocks CXCR4, circulating monocyte numbers rose and more monocytes infiltrated the brain. In other words, the interferon-driven marrow environment was effectively imprisoning the very cells the brain needed, trapping them at their site of production rather than releasing them to patrol the diseased nervous system.

The therapeutic implications were tested in two complementary ways. First, the researchers blocked type I interferon signaling with neutralizing antibodies against IFNAR1, the interferon receptor chain. Second, they transplanted bone marrow from IFNAR1-deficient donor mice into 5xFAD recipients, creating chimeric animals whose blood system could no longer respond to the cytokine. In both approaches, myelopoiesis was restored, monocyte phenotypes normalized, and, importantly, the number of monocyte-derived macrophages homing to the brain increased. The brains of the treated animals showed ameliorated disease pathology, including reduced synaptophysin-positive dystrophic neurites in the hippocampal CA1 region and decreased phospho-tau signal, alongside shifts in the composition and function of brain-resident myeloid cells. Cell-cell communication analysis revealed that the infiltrating cells re-engaged in productive interactions with microglia and other brain cells.

The study fits into a growing body of evidence that Alzheimer’s disease is not solely a brain disease but a systemic condition involving the entire neuroimmune axis. Recent work has shown that the skull and vertebral bone marrow serve as dedicated myeloid cell reservoirs for the brain’s protective membranes, communicating with the central nervous system through specialized vascular channels and cerebrospinal fluid routes. Other studies have linked bone marrow hematopoiesis to the progression of multiple sclerosis, and epidemiological analyses have connected systemic infections to subsequent dementia risk. The new findings add a critical layer to this picture: it is not just that peripheral immune cells influence the brain, but that the disease process reaches into the immune system’s factory and corrupts its output, creating a vicious cycle in which a failing brain fails to summon its own repair crew.

There are important caveats. The work relies heavily on the 5xFAD and APP knock-in mouse models, which recapitulate amyloid pathology but not the full complexity of human Alzheimer’s disease, and the human data come from reanalysis of existing datasets rather than from newly collected patient cohorts. Bone marrow transplantation and systemic interferon blockade are aggressive interventions with substantial clinical risks, and the researchers themselves note that translating these findings into therapy will require far more targeted approaches. Still, the identification of a druggable pathway, type I interferon signaling in the bone marrow, that controls both immune cell production and brain homing opens a genuinely new therapeutic frontier. It suggests that future treatments for Alzheimer’s might one day aim not only at plaques and tangles within the brain, but at restoring the health of the immune system that stands ready to defend it.

For a field that has endured repeated disappointments in clinical trials targeting amyloid and tau, the message of this study is both sobering and invigorating. It reframes Alzheimer’s disease as a failure of communication between the brain and the body’s immune headquarters, and it pinpoints a specific molecular saboteur, chronic type I interferon, that can be measured, modeled, and potentially neutralized. If the bone marrow dysfunction observed in mice and echoed in human patients proves to be a driver rather than merely a bystander of disease progression, then the road to effective treatment may run not through the brain itself, but through the quiet factories of blood cells hidden in our bones.

Subject of Research: Bone marrow myelopoiesis dysfunction and type I interferon signaling in Alzheimer's disease

Article Title: Bone marrow myelopoiesis dysfunction in Alzheimer’s disease limits monocyte homing to the brain and drives disease progression

Article References: Abellanas, M. A., Basurco, L., Purnapatre, M., Burgaletto, C., Castellani, G., Colaiuta, S. P., Peralta-Ramos, J. M., Ibraheem, A., Murad, S., Antonello, P., Kovacs, M., Androsova, Y., Nathansohn, B., Partney, H., Cahalon, L., Valdes-Mas, R., Josephides, J. M., Salame, T. M., Espelosin, M., … Schwartz, M. (2026). Bone marrow myelopoiesis dysfunction in Alzheimer’s disease limits monocyte homing to the brain and drives disease progression. Nature Neuroscience. https://doi.org/10.1038/s41593-026-02417-7

Image Credits: AI Generated

DOI: 10.1038/s41593-026-02417-7

Keywords: Alzheimer's disease, bone marrow, myelopoiesis, monocytes, type I interferon, macrophages, microglia, neuroimmunology, hematopoietic stem cells, CXCR4, 5xFAD mouse model, brain homing

The study, summarized in a Research Briefing in Nature Aging by a team led by Estefanía Gabandé-Rodríguez and colleagues, demonstrates that cytotoxic CD4+ T cells that accumulate in the bone marrow with age promote myelopoiesis—the generation of myeloid cells—through the chemokine axis CCL5–CCR5. CCL5, also known as RANTES, is a chemokine secreted by activated T cells, and CCR5 is its receptor, a molecule already famous in immunology as a co-receptor for HIV entry and the target of the clinically approved antiretroviral drug maraviroc. The researchers found that blocking this axis, either genetically or pharmacologically, could partially restore a more youthful balance between lymphoid and myeloid output in aged mice, positioning maraviroc as an unexpected candidate for immune rejuvenation.

The clinical significance of myeloid skewing is underscored by converging evidence from human cohort studies. A 2024 follow-up analysis of the Baltimore Longitudinal Study on Aging reported that the neutrophil-to-lymphocyte ratio, a simple clinical measure that rises as myelopoiesis gains the upper hand, predicts both multimorbidity and all-cause mortality in a cohort of 1,769 older participants. In other words, the degree to which the immune system tips toward myeloid cells is not merely a correlate of aging but appears to carry prognostic weight for health span and survival. Understanding the mechanisms that drive this skewing therefore has implications that extend well beyond basic hematology.

The new work builds on an intriguing earlier observation from cancer immunology. In 2018, researchers reported that T cells become sequestered in the bone marrow of patients with glioblastoma and other intracranial tumors, as well as in tumor-bearing mice, effectively hiding a substantial pool of lymphocytes away from the circulation. The aged bone marrow appears to recapitulate aspects of this phenomenon. As animals and humans grow older, cytotoxic CD4+ T cells increasingly take up residence in the bone marrow niche, where they sit in close proximity to hematopoietic stem and progenitor cells, the factories from which all blood cell lineages emerge. What those T cells do once they arrive has now been clarified.

The mechanistic story revealed by the study centers on CCL5 secretion. Cytotoxic CD4+ T cells in the aged marrow produce abundant CCL5, which engages CCR5 expressed on hematopoietic stem and progenitor cells. This signaling input pushes the differentiation program of the progenitors toward the myeloid lineage, amplifying the production of neutrophils and monocytes while constraining lymphoid output. The researchers demonstrated that interfering with this axis ameliorates the age-associated hematopoietic dysfunction that accompanies the accumulation of cytotoxic CD4+ T cells. Notably, treatment with maraviroc—a drug already in the clinic, with a well-characterized safety profile from two decades of use in HIV therapy—was able to rebalance immunity in aged mice, offering a plausible route to clinical translation.

The finding resonates strongly with parallel work in autoimmune disease. A 2022 study in Cell showed that bone marrow hematopoiesis drives the progression of multiple sclerosis, and that autoreactive CD4+ T cells fuel this process by secreting CCL5, thereby driving myelopoiesis during autoimmune neuroinflammation. The new study effectively extends that paradigm from pathological inflammation to physiological aging: the same molecular circuit that autoreactive T cells exploit to escalate neuroinflammation appears to operate quietly in the aged marrow, where cytotoxic CD4+ T cells gradually remodel the composition of the blood. Aging, in this view, co-opts an inflammatory program normally associated with disease.

The role of cytotoxic CD4+ T cells in aging is, however, far from one-dimensional, and the authors situate their findings within a rapidly evolving literature. Recent work has shown that CD4+ cytotoxic T lymphocytes can eliminate senescent cells—damaged, growth-arrested cells that accumulate in tissues and secrete inflammatory factors—by targeting cytomegalovirus antigens presented on HLA class II molecules. Senescent cells in human skin upregulate HLA-II and human cytomegalovirus glycoprotein B, rendering them recognizable targets for CD4+ cytotoxic killing. Another 2026 study reported that these cells expand adaptively in supercentenarians, driven by persistent exposure to tumor antigens, and may contribute to exceptional longevity through sustained cancer surveillance. Cytotoxic CD4+ T cells, in other words, can be agents of protection as well as drivers of age-associated pathology.

This duality raises important questions about the wisdom of simply depleting or suppressing these cells in older individuals. On one hand, their CCL5-mediated influence on the bone marrow clearly exacerbates myeloid bias and the pro-inflammatory microenvironment it creates. On the other, their surveillance functions—clearing senescent cells and hunting virus-infected or transformed cells—may be essential to healthy aging. The appeal of the CCL5–CCR5 intervention strategy is precisely that it does not require eliminating the cells themselves. By pharmacologically dampening the signaling conversation between cytotoxic CD4+ T cells and hematopoietic progenitors, maraviroc may dissociate the harmful hematopoietic effects of these cells from their beneficial cytotoxic functions, rebalancing the immune system while leaving its defensive capacities intact.

The study also highlights how much of immunological aging is orchestrated in the bone marrow itself rather than in peripheral tissues. The marrow is not a passive reservoir of blood cells but an active endocrine-like niche in which infiltrating lymphocytes, stromal cells and hematopoietic stem cells exchange signals that shape systemic immunity. With age, the accumulation of cytotoxic CD4+ T cells within this niche converts it into a factory for pro-inflammatory myeloid output, with downstream consequences for tissues throughout the body. Whether similar CCL5-driven mechanisms operate in other contexts of chronic T cell marrow sequestration, and whether maraviroc or related CCR5 antagonists can improve clinically meaningful outcomes such as infection resistance, vaccine responses or inflammatory disease burden in aged humans, will be the critical next steps. For now, the study offers a mechanistically precise and clinically actionable model of how the aging immune system tips toward inflammation—and a familiar drug that may help tip it back.

Subject of Research: The role of cytotoxic CD4+ T cells in driving age-associated myelopoiesis via CCL5–CCR5 signaling and its pharmacological reversal by maraviroc in aged mice.

Article Title: Cytotoxic CD4+ T cells support age-associated myelopoiesis

Article References: Cytotoxic CD4+ T cells support age-associated myelopoiesis. (2026). Nature Aging. https://doi.org/10.1038/s43587-026-01241-9

Image Credits: AI Generated

DOI: 10.1038/s43587-026-01241-9

Keywords: immunology, aging, hematopoiesis, cytotoxic CD4+ T cells, CCL5–CCR5 axis, myelopoiesis, maraviroc, bone marrow, inflammaging, Nature Aging, senescent cells, immune rejuvenation

The central discovery is that a signaling molecule called type I interferon, released as part of the body’s innate antiviral and inflammatory response, acts as the culprit. In mouse models of Alzheimer’s amyloidosis, the researchers found that this signal hijacks the bone marrow’s myelopoiesis machinery, the carefully regulated production line that generates monocytes and other myeloid cells. The result is a fundamental reprogramming of the marrow: healthy monocyte output falls, and with it the supply of monocyte-derived macrophages that would normally travel through the bloodstream, cross into the brain and help clear amyloid deposits.

That supply chain matters more than many researchers once assumed. Microglia, the resident immune cells of the brain, mount the first line of defense against amyloid accumulation, but decades of evidence suggest they cannot manage the burden alone. Monocyte-derived macrophages act as reinforcements, arriving from the periphery when microglia fall short. Earlier work has shown that blocking the CCR2-dependent recruitment of these peripheral cells accelerates Alzheimer-like pathology in mice, a finding that hinted at their protective role. The new study explains one mechanism by which that reinforcement pipeline breaks down: the disease itself sabotages the factory that produces the workers.

The technical core of the research centers on the 5xFAD mouse model, a widely used strain engineered to carry mutations that drive aggressive amyloid-beta production and reproduce key features of Alzheimer’s pathology. Using this model, the team traced how type I interferon signaling reshapes hematopoiesis, the continuous process by which blood and immune cells are generated from hematopoietic stem cells in the marrow. Under chronic type I interferon exposure, the balance of myeloid cell output shifts away from the populations needed for brain defense, effectively redirecting the immune system’s production capacity at the worst possible moment.

The most striking result came from blocking the aberrant signal. When the researchers interfered with type I interferon signaling in the periphery of 5xFAD mice, healthy monocyte output from the bone marrow was restored. The consequences cascaded outward: protective monocyte-derived macrophages once again reached the brain, amyloid-related disease manifestations were alleviated, and the animals’ overall pathology improved. In other words, correcting a fault in the peripheral immune system produced measurable benefits in the brain, without directly targeting plaques, tau or neurons.

This finding reframes the therapeutic landscape. Most Alzheimer’s drug development has concentrated on the brain itself, targeting amyloid and tau directly or attempting to modulate neuroinflammation inside the central nervous system. The new work argues for a fundamentally different entry point: the peripheral immune system as a therapeutic target. If the marrow’s production line can be protected or restored, the brain’s own defenses might be reinforced from the outside in, complementing or even improving on approaches that act within neural tissue.

The idea that peripheral interferon signaling shapes brain health has been building for years. Prior research showed that an aging-induced type I interferon response at the choroid plexus, the interface that guards the brain’s fluid-filled ventricles, negatively affects brain function and contributes to cognitive decline, establishing that interferon signals at the brain’s borders can be harmful. Separate work demonstrated that activation of the cGAS–STING innate immune DNA-sensing pathway drives type I interferon signaling and contributes to pathology in 5xFAD mice. The new study extends this line of inquiry from the brain’s border checkpoints all the way back to the bone marrow, connecting these threads into a coherent peripheral-to-central narrative of immune dysfunction in Alzheimer’s disease.

Technically, the work exemplifies the growing field of neuroimmunology, which maps the dense bidirectional communication between the nervous system and the immune system. The bone marrow, blood, meninges and brain parenchyma form a continuous immune circuit, and disruptions at any node can propagate. Alzheimer’s disease, on this view, is not simply a neurodegenerative process with some incidental inflammation attached; it is a systemic condition in which the brain’s pathology actively reprograms distant immune organs, and in which those reprogrammed organs then fail to provide the support the brain desperately needs. The type I interferon axis appears to be a key transmission channel for this vicious cycle.

There are important caveats and open questions. The findings were established in the 5xFAD model, which reproduces amyloid-driven aspects of the disease but does not capture the full complexity of human Alzheimer’s, including tau pathology, neuronal loss and the disease’s heterogeneous course in people. Whether the same bone marrow myelopoiesis dysfunction occurs in human patients, and whether it correlates with disease stage, remains to be demonstrated. Translating the intervention to the clinic would also require identifying safe ways to modulate type I interferon signaling, a pathway central to antiviral immunity, without leaving patients vulnerable to infection or unleashing broader immune disruption.

Even so, the study opens an unusually concrete research agenda. Biomarkers of peripheral myelopoiesis could be developed to monitor immune reprogramming in patients, and drugs already approved for other interferon-driven conditions might be repurposed to test whether restoring marrow output benefits the brain. More broadly, the work adds Alzheimer’s disease to the growing list of neurological disorders, from multiple sclerosis to aging-related cognitive decline, in which the peripheral immune system is not a bystander but an active participant whose failure or manipulation shapes the course of disease. The bone marrow, long the province of hematologists, may soon claim a place in the neuroscience of dementia, as researchers pursue therapies that treat the brain’s defenses as a whole-body enterprise.

Subject of Research: Bone marrow myelopoiesis dysfunction and type I interferon signaling in Alzheimer's disease

Article Title: The hidden role of the bone marrow in Alzheimer’s disease

Article References: The hidden role of the bone marrow in Alzheimer’s disease. (2026). Nature Neuroscience. https://doi.org/10.1038/s41593-026-02418-6

Image Credits: AI Generated

DOI: 10.1038/s41593-026-02418-6

Keywords: Alzheimer's disease, bone marrow, type I interferon, myelopoiesis, monocyte-derived macrophages, neuroimmunology, 5xFAD mouse model, amyloid-beta, microglia, peripheral immune system, cGAS-STING, therapeutic target